People In The News: Tracking The Latest Industry Personnel Moves
New top leadership at Critical Path Institute, NeurogesX; Former CMS Acting Administrator Frizzera joins FaegreBD Consulting. More personnel moves in this month’s column.
You may also be interested in...
Former Savient and ImClone CEO Johnson will be responsible for driving commercial expansion of Provenge in the U.S. and Europe. Mitchell Gold steps down as CEO after successfully getting the prostate cancer drug to market following an arduous FDA review but struggling with commercial complexities.
During nine years at Ben Venue, Gaugh was responsible for strategic planning, financial management, business development, marketing and sales for the company’s $500 million branded generic injectable business, which is now struggling with manufacturing challenges.
Most of the top 20 generic drug makers are subsidiaries of diversified pharmas or smaller generics-only plays based in the Far East. But diversification, although long a goal, is now urgent for the three major independent generic firms – Teva, Mylan and Watson.